Financial Performance - For the fiscal year ending December 31, 2024, the company reported total revenue of RMB 155.74 million, a slight decrease of 0.2% compared to RMB 156.07 million in 2023[5][13]. - Gross profit for 2024 was RMB 62.79 million, down from RMB 85.41 million in 2023, indicating a significant decline in profitability[5]. - Net profit attributable to shareholders for 2024 was RMB 17.20 million, a decrease from RMB 27.57 million in 2023, reflecting a challenging market environment[5]. - Total revenue decreased by 0.2% to approximately RMB 155.7 million, primarily due to a decline in sales of medical imaging film products and cloud services[37]. - Sales revenue from medical imaging film products and software increased by approximately RMB 5.4 million or 3.8% to about RMB 146.5 million, despite a decrease in film product sales revenue by approximately RMB 23.1 million to about RMB 118.0 million[37]. - Revenue from medical imaging cloud services decreased by approximately RMB 5.7 million or 38.4% to about RMB 9.2 million, mainly due to the decline in film product sales[38]. - Cost of sales increased by 31.5% to approximately RMB 93.0 million, driven by a 36.6% increase in the quantity of medical imaging film products sold to 16.7 million pieces[39]. - Gross profit decreased by RMB 22.6 million to approximately RMB 62.8 million, with a gross margin decline of about 14.4 percentage points to approximately 40.3%[40]. - Other income and gains increased by approximately RMB 6.2 million or 259.6% to about RMB 8.6 million, mainly due to an increase in government subsidy income[41]. - Net profit decreased by approximately RMB 10.4 million or 37.5% to about RMB 17.5 million, with a net profit margin decline to approximately 11.2%[46]. Assets and Liabilities - Total assets as of December 31, 2024, amounted to RMB 304.2 million, with a debt-to-asset ratio of 6.8%[13]. - Non-current assets increased to RMB 58.69 million in 2024, up from RMB 40.30 million in 2023, indicating growth in long-term investments[6]. - Current assets decreased to RMB 245.48 million in 2024 from RMB 272.19 million in 2023, reflecting a reduction in short-term liquidity[6]. - As of December 31, 2024, net current assets were approximately RMB 202.0 million, down from RMB 230.4 million[47]. - The company had outstanding interest-bearing bank loans of RMB 17.7 million as of December 31, 2024, down from RMB 21.1 million[50]. Market Strategy and Operations - The company plans to increase investment in medical imaging film products to strengthen its market position in Shandong province[14]. - The medical imaging film market remains significant, particularly in grassroots medical institutions where physical archiving is still required[14]. - The company is accelerating the sales of its medical imaging cloud services, which include four types of platforms, in response to the trend towards digital transformation in healthcare[14]. - In 2024, the company expanded its sales team by 9 personnel, enhancing local market understanding and customer engagement, which is expected to improve brand penetration and customer satisfaction[15]. - The company plans to expand its customer base and strengthen its market position in Shandong Province through strategic acquisitions and upgrades to medical imaging cloud services[28]. - The company is advancing its digital transformation by developing new products, including X-ray machines and endoscopes, which are currently in the registration and inspection stages[17]. - The company is collaborating with Xiamen University to develop AI systems for medical imaging, aiming to enhance diagnostic efficiency and accuracy, with some products already receiving NMPA/FDA certification[18]. - The company is developing AI-assisted diagnostic software to support medical professionals during the diagnostic process, leveraging advancements in artificial intelligence and machine learning[29]. - The company recognizes the growing demand for digital medical imaging and aims to capitalize on the transition from traditional film to digital formats[34]. Risk Management - The company emphasizes the importance of financial risk control, focusing on inventory management and preventing capital recovery risks[33]. - The company is committed to strengthening operational risk management through staff training and establishing effective recall systems for medical devices[31]. - The company has implemented financial risk management policies to address interest rate, credit, and liquidity risks[75]. - The company has identified and assessed significant risks that may affect its business and operations[198]. - The company is aware of potential regulatory changes in China that could impact its operations, particularly regarding the implementation of health information platforms[82]. Corporate Governance - The company has adopted the corporate governance code as per the listing rules and has complied with it throughout the year[155]. - The board consists of two executive directors, one non-executive director, and three independent non-executive directors, meeting the requirement of at least one-third independent members[160]. - The company has a commitment to promoting gender diversity at all levels, with one female director among the six board members[166]. - The board has established three committees: audit committee, remuneration committee, and nomination committee, to oversee specific aspects of governance[157]. - The audit committee has reviewed the consolidated financial statements for the year, which have been agreed upon by the independent auditor[140]. - The company has maintained a public float of at least 25% of its issued shares throughout the year[148]. - The company has a liability insurance policy in place for directors and senior management, effective as of the report date[176]. - The board has engaged an external professional service company to conduct an annual review of the risk management and internal control systems for the year ending December 31, 2024[200]. Employee and Management - The company has a strong focus on human resources management, aiming to provide competitive compensation and training opportunities, with an average employee tenure of approximately four years[83]. - The total number of employees as of December 31, 2024, is 57, with a gender ratio of approximately 2:1 (41 male and 16 female employees)[167]. - The company has not faced any significant disputes with employees in the past three years, ensuring smooth business operations[83]. - The compensation policy ensures competitive remuneration and benefits for all employees, reviewed regularly based on performance and market trends[127]. - Each director participated in training courses covering their responsibilities and corporate governance, ensuring ongoing professional development[174]. Shareholder Information - The board does not recommend the payment of a final dividend for 2024, compared to a dividend of HKD 0.021 per share in 2023[58]. - The company has a reserve of approximately RMB 12,234,000 available for distribution to shareholders as of December 31, 2024[93]. - The planned use of the net proceeds includes expanding the customer base and strengthening market position (46.4% of the proceeds) and enhancing medical imaging cloud services (37.3%)[98]. - As of December 31, 2024, Mr. Meng Xianzheng holds 700,574,575 shares, representing 73.74% of the company's issued share capital[107]. - Meng A Capital, wholly owned by Mr. Meng, also holds 700,574,575 shares, accounting for 73.74% of the issued share capital[113]. Audit and Compliance - Ernst & Young has been appointed as the auditor for the year ending December 31, 2024[151]. - The company has no significant disagreements with the external auditor regarding the annual audit services provided[182]. - The audit committee convened 3 times during the year, reviewing the company's annual report and financial statements[180]. - The company has not made any charitable donations during the year[150].

Financial Performance - The total revenue for the year ended December 31, 2024, was RMB 155,740,000, a slight decrease of 0.2% compared to RMB 156,072,000 in 2023[3] - Gross profit decreased to RMB 62,786,000, down 26.5% from RMB 85,405,000 in the previous year[3] - The net profit for the year was RMB 17,450,000, a decline of 37.5% from RMB 27,922,000 in 2023[4] - Basic and diluted earnings per share decreased to RMB 0.02 from RMB 0.03 in the previous year[4] - Operating revenue for the year ended December 31, 2024, was approximately RMB 155.7 million, a slight decrease from RMB 156.1 million in 2023[14] - The total revenue recognized for the year ended December 31, 2024, was RMB 155.74 million, a decrease of 0.2% from RMB 156.07 million in 2023[17] - The company's profit attributable to equity holders for the year ended December 31, 2024, was RMB 17.2 million, a decrease of 37.5% from RMB 27.6 million in 2023[29] - The group's profit for the year decreased by approximately RMB 10.4 million or 37.5% to about RMB 17.5 million, with a net profit margin declining to approximately 11.2%[65] Revenue Breakdown - Revenue from medical imaging film products accounted for about 76% of total revenue for the year ended December 31, 2024, down from 90% in 2023[14] - Revenue from software sales reached RMB 28.5 million in 2024, compared to zero in 2023, indicating a new revenue stream[17] - Revenue from medical imaging film products and software sales rose to RMB 146.5 million in 2024, up 3.8% from RMB 141.1 million in 2023, driven by increased software sales[43][44] - Revenue from medical imaging cloud services dropped 38.4% to approximately RMB 9.2 million in 2024, down from RMB 14.9 million in 2023, primarily due to decreased sales of imaging film products[45] Expenses and Costs - The cost of goods sold for the year ended December 31, 2024, was RMB 90.7 million, an increase from RMB 68.5 million in 2023[25] - Research and development expenses increased significantly to RMB 4,068,000, compared to RMB 1,528,000 in 2023, reflecting a focus on innovation[3] - Selling and distribution expenses decreased by approximately RMB 8.8 million or 32.9% to about RMB 17.8 million (2023: RMB 26.6 million) due to reduced channel fees paid to distributors[61] - Administrative expenses decreased by 4.0% to approximately RMB 13.8 million (2023: RMB 14.3 million)[62] - Financial costs decreased by approximately RMB 0.2 million or 17.5% to about RMB 0.7 million (2023: RMB 0.9 million) primarily due to no bill discounting interest in the current year[63] Assets and Liabilities - Non-current assets increased to RMB 58,686,000, up from RMB 40,301,000 in 2023, indicating growth in long-term investments[5] - Trade receivables rose to RMB 174,190,000 from RMB 120,175,000, suggesting an increase in sales on credit[5] - Current liabilities totaled RMB 43,507,000, a slight increase from RMB 41,783,000 in 2023, indicating a stable financial position[5] - The total equity decreased to RMB 260,506,000 from RMB 270,318,000, reflecting a reduction in retained earnings[6] - The expected credit loss for trade receivables was RMB 7.95 million in 2024, an increase from RMB 4.75 million in 2023[34] - Trade payables decreased to RMB 0.56 million in 2024 from RMB 1.38 million in 2023, indicating improved cash flow management[39] Government Support and Grants - The company received government grants totaling RMB 7.56 million in 2024, a substantial increase from RMB 1.51 million in 2023[23] - Other income and gains increased by approximately RMB 6.2 million or 259.6% to about RMB 8.6 million (2023: RMB 2.4 million), mainly due to an increase in government subsidies by RMB 6.1 million to about RMB 7.6 million (2023: RMB 1.5 million)[60] Strategic Focus and Future Outlook - The company continues to focus on expanding its medical imaging cloud services and software sales as part of its growth strategy[10] - The company plans to expand its customer base in Shandong Province and strengthen its market position through strategic acquisitions and upgrades to its software and hardware offerings[46] - The company anticipates that 2024 will be a pivotal year for the commercial application of AI in healthcare, aligning with national policies supporting AI medical applications[48] - The implementation of the "two-invoice system" in the medical imaging film industry may adversely affect the company's operations and financial performance[47] Corporate Governance and Compliance - The company has adopted a standard code of conduct for directors and employees regarding insider trading, with no violations reported during the year[84] - The audit committee, consisting of three independent non-executive directors, has reviewed the group's accounting principles and internal controls, confirming compliance with applicable accounting standards[91] - The company has adopted the corporate governance code and believes it has fully complied with it during the year, with some exceptions noted[85] Shareholder Information - The company did not declare a final dividend for 2024, compared to a final dividend of HKD 0.021 per share in 2023[28] - The annual general meeting is scheduled for May 30, 2025, with a suspension of share transfer registration from May 27 to May 30, 2025, to determine eligible shareholders[86][87] - The independent auditor, Ernst & Young, has agreed that the financial figures in the preliminary announcement align with the consolidated financial statements for the year ending December 31, 2024[92] - The company expresses gratitude to shareholders and stakeholders for their continued support and acknowledges the contributions of all employees[94]

Guanze Medical Information Industry (Holding) Co., Ltd. Stock Code: 2427 (Incorporated in the Cayman Islands with limited liability) Interim Report 2024 Interim Report 2024 中期報告 股份代號：2427 (於開曼群島註冊成立的有限責任公司) 中期報 告 2024 目錄 公司資料 2 管理層討論及分析 3 企業管治及其他資料 13 獨立審閱報告 20 中期簡明綜合損益及其他全面收益表 21 中期簡明綜合財務狀況表 22 中期簡明綜合權益變動表 23 中期簡明綜合現金流量表 24 中期簡明綜合財務資料附註 25 公司資料 | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------- ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 – 1 – Guanze Medical Information Industry (Holding) Co., Ltd. （於開曼群島註冊成立的有限責任公司） （股份代號：2427） 截至2024年6月30日止六個月 中期業績公告 董事會欣然宣佈本集團截至2024年6月30日止六個月之未經審核簡明綜合中期 業績如下： 中期簡明綜合損益及其他全面收益表 截至2024年6月30日止六個月 | --- | --- | --- | --- | |------------------------------------------|-------|----------------------------------------------------|------------------------------------------------| | | 附註 | 截至 6 月 30 \n2024 年 \n（ ...

Financial Performance - For the year ended December 31, 2023, the group's revenue was RMB 156.1 million, with RMB 141.1 million generated from the sale of medical imaging film products and RMB 15.0 million from providing medical imaging cloud services[193]. - The audit report confirms that the consolidated financial statements fairly reflect the group's financial position as of December 31, 2023, in accordance with Hong Kong Financial Reporting Standards[177]. - The company utilizes a cloud platform to provide integrated medical imaging information technology services, which includes significant judgment and estimates in revenue recognition[179]. - The audit identified key audit matters related to revenue recognition and the identification of performance obligations[192]. - The company must disclose significant accounting judgments and estimates in the financial statements[194]. - The audit procedures included reviewing customer agreements and orders to assess the revenue recognition policy[195]. - The company is responsible for ensuring that the consolidated financial statements are free from material misstatement due to fraud or error[198]. Share Issuance and Incentive Plans - The company issued 192,850,000 shares at a price of HKD 0.53 per share, raising approximately HKD 76.8 million (equivalent to about RMB 68.6 million) from the global offering[18]. - As of December 31, 2023, a total of 47,500,000 shares are available for grant under the share incentive plan, representing 5% of the issued shares as of the adoption date[38]. - The company plans to grant a total of 6,802,000 shares to 16 selected participants at zero cost on January 6, 2024, which will vest on January 5, 2029, accounting for approximately 0.72% of the issued shares[37]. - The company granted a total of 6,802,000 shares as reward shares to 16 selected employees, representing approximately 0.72% of the issued shares as of the adoption date, with vesting scheduled for January 5, 2029[68]. - The company adopted a share incentive plan on December 2, 2023, aimed at rewarding eligible participants for their contributions and enhancing performance[36]. Governance and Compliance - The company has complied with relevant laws and regulations in China during the fiscal year, as confirmed by the board[9]. - The company does not anticipate significant environmental compliance costs or liabilities from its operations, which do not produce industrial pollutants[8]. - The company has not entered into any significant transactions or agreements with any controlling shareholders during the year[33]. - The company has complied with the terms of the non-competition agreement during the year[61]. - The company has no significant contracts for managing or handling any part of its business with any individual or entity during the year[63]. - The audit committee, along with management and independent auditors, confirmed that the company's annual performance complies with applicable accounting standards and regulations[39]. - The company has committed to anti-corruption policies, ensuring compliance with applicable laws and regulations[148]. Risk Management - The company’s financial risk management policies are outlined in the consolidated financial statements, addressing interest rate, credit, and liquidity risks[6]. - The risk management and internal control system is overseen directly by the board, which has not established an internal audit function due to the scale and complexity of the business[146]. - The company has engaged external consultants to review its risk management and internal control systems annually[164]. - The audit committee met twice to discuss the annual report and evaluate the company's risk management measures[136]. - The company has a whistleblowing policy for employees and stakeholders to report serious concerns confidentially[147]. Board Structure and Meetings - The board consists of two executive directors, one non-executive director, and three independent non-executive directors, ensuring at least one-third of the board members are independent[104]. - The board held 4 meetings during the year to discuss business strategies, operations, and financial performance[87]. - The audit committee is composed of three members, all of whom are independent non-executive directors, ensuring compliance with the relevant listing rules[104]. - The company has established three board committees: the audit committee, the remuneration committee, and the nomination committee, to oversee specific areas of governance[102]. - The remuneration committee held 2 meetings during the year to review and approve the remuneration proposals for the management team[139]. - The nomination committee held one meeting during the fiscal year to review board structure and diversity policies[158]. - The board meets regularly, with a minimum of four scheduled meetings per year, ensuring adequate oversight and decision-making[111]. Shareholder Communication - The company has established a shareholder communication policy, which is reviewed annually by the board[184]. - The board believes there is effective communication between shareholders and the company as of December 31, 2023[185]. - The board of directors emphasizes the importance of ongoing communication with shareholders, encouraging attendance at annual general meetings[151]. - The company believes effective communication with shareholders is crucial for enhancing investor relations and understanding business performance[171]. - The company has a dedicated website providing extensive financial and governance information for public investors[172]. Employee and Diversity - The total number of employees as of December 31, 2023, was 56, an increase from 43 in 2022, with a gender ratio of approximately 2:1 (39 male and 17 female employees)[85]. - The company aims to maintain appropriate diversity among its directors, promoting gender diversity at all levels, with one female director among the six[109]. - The board has committed to continuous professional development for all directors, encouraging participation in training courses and seminars[117]. - Each independent non-executive director has a specific term and must retire at least once every three years, ensuring fresh perspectives on the board[106]. - The company has implemented appropriate liability insurance for its directors and senior management, providing indemnity against potential lawsuits[118].

智通财经APP讯，GUANZE MEDICAL(02427)发布截至2023年12月31日止年度业绩，该集团期内取得收入1.56亿元(人民币，下同)，同比减少11.88%;母公司拥有人应占溢利2756.7万元，同比增加53.63%;每股基本盈利0.03元;拟派发末期股息每股2.1港仙。 公告称，收入减少主要由于销售医用影像胶片产品收入减少。年内医用影像胶片产品的销售收入减少约1640万元或10.4%至约1.41亿元(2022年：1.58亿元)。主要因为客户的需求逐步从国际品牌影像胶片转移到集团的自有品牌医用影像胶片。 ...

Financial Performance - The total revenue for the year ended December 31, 2023, was RMB 156,072,000, a decrease of 11.9% compared to RMB 177,112,000 in 2022[1] - Gross profit increased to RMB 85,405,000, up 5.6% from RMB 80,976,000 in the previous year[1] - The net profit for the year was RMB 27,922,000, representing a significant increase of 52.6% from RMB 18,286,000 in 2022[1] - Basic earnings per share for the parent company shareholders rose to RMB 0.03, compared to RMB 0.02 in 2022[2] - The cost of goods sold for the year ended December 31, 2023, was RMB 68,508,000, down from RMB 92,977,000 in 2022, indicating a reduction of approximately 26.4%[53] - The total tax expense for the year ended December 31, 2023, was RMB 10,728,000, slightly lower than RMB 11,676,000 in 2022, representing a decrease of approximately 8.1%[54] - Net profit increased by approximately RMB 9.6 million or 52.7% to about RMB 27.9 million (2022: RMB 18.3 million), with a net profit margin growth to approximately 17.9% (2022: 10.3%) due to reduced financial costs and tax expenses[145] Revenue Breakdown - For the year ended December 31, 2023, total revenue from the sale of medical imaging film products was RMB 141,137,000, while revenue from medical imaging cloud services was RMB 14,935,000[25] - The revenue breakdown for the year ended December 31, 2023, was 90% from medical imaging film products and 10% from medical imaging cloud services, compared to 89% and 11% in 2022 respectively[44] - Revenue from medical imaging film products was RMB 141.1 million, a decrease of 10.4% from RMB 157.5 million in 2022[97] - Revenue from medical imaging cloud services decreased by 23.8% to approximately RMB 14.9 million (2022: RMB 19.6 million), mainly due to the corresponding decrease in sales of medical imaging film products[127] Assets and Liabilities - Non-current assets totaled RMB 40,301,000, an increase from RMB 34,646,000 in 2022[3] - Current assets decreased to RMB 272,192,000 from RMB 293,077,000 in 2022, primarily due to a reduction in inventory[3] - The company’s total liabilities decreased from RMB 1,585,000 in 2022 to RMB 1,032,000 in 2023, indicating improved financial stability[48] - The group’s asset-liability ratio decreased by 2.0% to 7.8% as of December 31, 2023, compared to 9.8% as of December 31, 2022, mainly due to a reduction in interest-bearing bank loans[184] Cash Flow - The company reported a significant increase in cash and cash equivalents, reaching RMB 68,350,000, compared to RMB 29,368,000 in the previous year[3] - The net cash generated from financing activities was approximately RMB 37.4 million, significantly up from RMB 9.1 million in 2022, primarily due to proceeds from the listing of approximately RMB 82.4 million[147] - The net cash used in investment activities for the year was approximately RMB 7.3 million, a decrease from RMB 9.3 million in 2022[147] - The net cash generated from operating activities for the year was approximately RMB 8.8 million, slightly down from RMB 9.3 million in 2022[163] Research and Development - Research and development expenses increased to RMB 1,528,000, up from RMB 542,000 in the previous year, indicating a focus on innovation[1] - Research and development expenses for the year ended December 31, 2023, were RMB 1,528,000, significantly higher than RMB 542,000 in 2022, reflecting an increase of approximately 182.5%[53] - The company is focused on developing AI systems to automate medical data processing, enhancing service levels and efficiency[103] - The company is developing AI-assisted diagnostic software to enhance diagnostic efficiency and support healthcare professionals[130] Customer and Market Strategy - The company plans to expand its customer base and strengthen its market position in eastern Shandong Province, while also upgrading its IT systems[128] - The company aims to control operational risks by improving inventory management and ensuring sales-based production budgeting[133] - The company maintains strong relationships with multiple distributors to expand its customer network in eastern Shandong Province[135] - The share of self-branded "Guanzhuihui" medical imaging film in total revenue rose from 44.1% in 2022 to 74.9% in 2023[97] Dividends and Shareholder Information - The proposed final dividend for the year ended December 31, 2023, is HKD 0.021 per share, unchanged from the previous year[56] - The company plans to propose a final dividend for the year ended December 31, 2023, subject to approval at the upcoming annual general meeting[79] - Basic earnings per share for the year ended December 31, 2023, were RMB 27.6 million, compared to RMB 17.9 million for 2022, with a weighted average of 950,000,000 shares issued in 2023, up from 766,132,055 shares in 2022[57] Employee Information - As of December 31, 2023, the company had a total of 56 employees, an increase from 43 employees as of December 31, 2022[190] Governance and Compliance - The company has adopted the corporate governance code and believes it has complied with the code throughout the year, with some exceptions noted[197]

Revenue Performance - Revenue from medical imaging film products was RMB 679 million, a decrease of 26.8% compared to RMB 928 million in the same period last year[8]. - The revenue for the period decreased by 24.5% to approximately RMB 744 million, down from RMB 986 million in the same period last year[20]. - Total revenue for the six months ended June 30, 2023, was approximately RMB 74.4 million, down from RMB 98.6 million in the same period of 2022, with medical imaging film sales contributing about 91% of total revenue[90]. - Revenue from medical imaging cloud services increased by 11.6% to approximately RMB 65 million from about RMB 58 million in the same period last year, driven by increased demand from existing customers[10]. - Revenue from individual customers accounted for over 10% of total revenue, totaling RMB 26,038,000 in 2023, compared to RMB 22,282,000 in 2022, representing an increase of approximately 16%[91]. Cost and Profitability - The gross profit margin increased due to a significant reduction in sales costs, with the self-owned brand "Guanze Huiyi" accounting for 50.3% of total revenue from medical imaging film products, up from 31.6% in the previous year[8]. - Gross profit increased by RMB 3.6 million to approximately RMB 43.2 million, with a gross margin increase of approximately 17.9 percentage points to about 58.1%[23]. - Sales cost decreased by 47.1% to approximately RMB 31.2 million, down from RMB 59.0 million for the six months ended June 30, 2022, primarily due to lower costs of in-house brand films[22]. - The cost of goods sold for the six months ended June 30, 2023, was RMB 29,753,000, down from RMB 57,567,000 in 2022, a decrease of approximately 48%[101]. Financial Position - As of June 30, 2023, the group recorded net current assets of approximately RMB 214.6 million, with cash and cash equivalents increasing by approximately RMB 41.8 million to about RMB 71.2 million[31]. - The group had outstanding interest-bearing bank loans of RMB 30.8 million as of June 30, 2023, compared to RMB 25.5 million as of December 31, 2022[34]. - The company maintained a strong balance sheet with net assets of RMB 258,462,000 as of June 30, 2023[78]. - Cash and cash equivalents increased significantly to RMB 71,214,000 as of June 30, 2023, compared to RMB 29,368,000 as of December 31, 2022, reflecting improved liquidity[78]. Strategic Initiatives - The company plans to expand its customer base and strengthen its market position in Shandong Province by extending operations to the eastern part of the province[12]. - Strategic acquisitions and upgrades of software and hardware are planned to enhance the supply of medical imaging cloud services[12]. - The company aims to expand its product portfolio to horizontally extend the value chain[12]. - Participation in trade exhibitions is intended to promote the brand and increase market visibility[12]. - The company aims to strengthen risk management by enhancing staff training and establishing a recall system for medical devices[15]. Research and Development - The company is committed to advancing research and development in medical imaging cloud services, anticipating significant growth in the coming years due to increasing acceptance of cloud computing in healthcare[17]. - Research and development costs rose to RMB 734,000, compared to RMB 185,000 in the same period last year, indicating a focus on innovation[76]. Governance and Compliance - The company has adopted the corporate governance code as per the listing rules and has complied with it, except for one specific provision[63]. - The board of directors remains committed to effective governance and oversight, ensuring a balanced authority structure[65]. Market Outlook - The Chinese medical imaging cloud service market is expected to grow from approximately RMB 3.5 billion in 2021 to about RMB 18.9 billion by 2030, with a compound annual growth rate (CAGR) of 20.6%[5]. - The Shandong province medical imaging cloud service market is projected to rise from approximately RMB 300 million in 2021 to about RMB 1.63 billion by 2030, with a CAGR of approximately 20.5%[5].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Guanze Medical Information Industry (Holding) Co., Ltd. （於開曼群島註冊成立的有限責任公司） （股份代號：2427） 有關截至2023年6月30日止六個月 中期業績公告的 澄清公告 茲提述Guanze Medical Information Industry (Holding) Co., Ltd（.「本公司」）日期為 2023年8月24日截至2023年6月30日止六個月的中期業績公告（「2023年中期業績公 告」）。除另有界定外，本公告所用詞彙與2023年中期業績公告所界定者具有相同 涵義。 本公司謹此澄清，由於無心之失，2023年中期業績公告第9頁附註5(c)「收入、其 他收入及收益」中「履約義務」項下有關「提供醫學影像雲服務」應修改如下（改正內 容以下劃線表示）： 提供醫學影像雲服務 醫學影像雲服務的履約義務乃於提供服務時逐步履行。由於服務連同 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就 因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損 失承擔任何責任。 Guanze Medical Information Industry (Holding) Co., Ltd. （於開曼群島註冊成立的有限責任公司） （股份代號：2427） 截 至2023年6月30日 止 六 個 月 中 期 業 績 公 告 董 事 會 欣 然 宣 佈 本 集 團 截 至2023年6月30日 止 六 個 月 之 未 經 審 核 簡 明 綜 合中期業績如下： 中期簡明綜合損益及其他全面收益表 截至2023年6月30日止六個月 截至6月30日止六個月 2023年 2022年 附註 人民幣千元 人民幣千元 （未經審核） （經審核） 收入 5 74,413 98,621 銷售成本 (31,184) (58,995) 毛利 43,229 39,626 其他收入及收益 5 2,024 1,640 ...